Mixed Phenotype Acute Leukemia (MPAL) is an understudied subtype of leukemia that shares features of acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML). Unfortunately, patients with MPAL have been left out of clinical trials, leading to a lack of standardized treatment. Instead, they may receive chemotherapies normally used for ALL or AML, and their outcomes remain poor. A better understanding of the disease is essential to design more efficient and targeted therapies. Rearrangements of the ZNF384 gene are a common genetic change in childhood MPAL.
